Norwalk, Conn., November 15, 2023 — The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Reverb Therapeutics to explore the potential of its antibody-based Amplifier™ platform for the treatment of multiple myeloma with endogenous cytokines that naturally occur within the body.
Reverb is a seed-stage oncology company with a highly differentiated platform approach to cytokine therapy. Its Amplifier™ platform uses antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines. Instead of using heavily engineered exogenous cytokines to treat diseases, which present challenges such as systemic toxicity and immunogenicity, Reverb’s antibodies redirect endogenous cytokines already in the body to cells of interest. With this round of funding, the MIF joins Reverb’s founding and lead investor Amplitude Ventures to support the company’s initial debut of its platform for the potential treatment of multiple myeloma and other cancers.
“We look forward to our partnership with Reverb Therapeutics and the potential of its Amplifier platform as a treatment for multiple myeloma,” said Michael Andreini, President and CEO at the Multiple Myeloma Research Foundation. “The MIF is committed to identifying and accelerating the most innovative treatment approaches for myeloma patients and we are excited by the potential of this novel approach to cytokine therapy.”
“We are excited about the power that the Myeloma Investment Fund brings to Reverb Therapeutics,” said David de Graaf, PhD, Founder and CEO of Reverb Therapeutics. “Having the scientific and clinical team at the MMRF available to an early-stage company is unique. We can translate their knowledge, focus, and dedication to improve the lives of multiple myeloma patients into impactful therapies such as our IL-15 programs.”
About the Myeloma Investment Fund
The Myeloma Investment Fund is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit www.myelomainvestmentfund.org
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, use data to drive optimal and more personalized treatment approaches, and empower myeloma patients with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has raised over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.
About Reverb Therapeutics
Based in Vancouver, Reverb Therapeutics is the leader in the development of treatments for cancer and other diseases using the body’s natural endogenous cytokines. Reverb’s Amplifier™ Antibody platform avoids the systemic toxicity normally associated with cytokine treatments by increasing cytokine levels only in targeted tissues. Elements of Amplifier antibodies are reusable, allowing Reverb to rapidly scale its pipeline across multiple disease areas. Learn more about opportunities to work with Reverb by contacting [email protected].
Multiple Myeloma Research Foundation Media Contact:
C.J. Volpe, Director, PR and Communications